RAD51C and breast cancer: Sixty-nine percent (67/97) of the patients with a positive test result harbored a P/LP in high-penetrance breast cancer genes (32% in BRCA1, 25.7% in BRCA2, 10.3% in PALB2 and 1% in TP53) and 15.4% (15/97) in moderate-penetrant breast cancer genes (7.2% in CHEK2, 4.1% in ATM, 2% in BARD1, 1% in RAD51C and 1% in RAD51D).